RxDoctor Payments Data

Marvin Moszkowicz, MD

Internal Medicine · San Antonio, TXNPI 1184612020

Payments from drug & device makers

$11,537in general payments, 2019–2025

Across 584 payments — averaging $19.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$2K
  • Sunovion Pharmaceuticals Inc.$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Astellas Pharma US Inc$941
  • Neurocrine Biosciences, Inc.$750
  • Novo Nordisk$476
  • plus $4K from 35 others

What the payments were for

  • Speaking & faculty fees$250%
  • Food & beverage$11,15397%
  • Education$3593%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,537 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$58,327
Medicare patients
230
Services billed
820

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin155$112,221
OzempicSemaglutide76$76,239
MounjaroTirzepatide49$52,017
EliquisApixaban147$48,346
TrulicityDulaglutide20$27,006
MyrbetriqMirabegron49$23,487
GemtesaVibegron33$22,650
JanuviaSitagliptin Phosphate30$18,605
RybelsusSemaglutide15$13,962
XareltoRivaroxaban44$13,617
Dexlansoprazole DrDexlansoprazole24$8,104
Levothyroxine Sodium333$4,986
Duloxetine Hcl74$4,726
Potassium Chloride129$4,024
Atorvastatin Calcium340$3,931

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$29$112,221155 claims
Novo NordiskOzempic, Rybelsus$476$90,20191 claims
Lilly USA, LLCMounjaro, Trulicity$192$79,02369 claims
PfizerEliquis$13$48,346147 claims
Astellas Pharma US IncMyrbetriq$941$23,48749 claims
Sumitomo Pharma America, Inc.Gemtesa$391$22,65033 claims
Johnson & JohnsonXarelto$364$13,61744 claims
Almatica Pharma LLCSertraline Hcl$129$1,939144 claims
Teva Pharmaceuticals USA, Inc.Albuterol Sulfate$1,427$1,71318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →